Journal: RSC Advances

Article Title: Targeting HER2-positive gastric cancer with a novel 18 F-labeled Z HER2:342 probe

doi: 10.1039/c8ra10271f

Figure Lengend Snippet: HER2 test with IHC staining and western blot. NCI N87 cells and tumors ((a) ×200 fold; (b) ×400 fold) exhibited strong positive expression of HER2. HER2 proteins were mainly located on the cell membrane surface (dyed dark brown). SGC 7901 cells and tumors showed weak staining ((c) ×200 fold; (d) ×200 fold) when compared with the NCI N87 groups. The western blot results in (e) represent the actin and HER2 in SGC7901 (left) and NCI N87 (right). The mean density ratio of NCI N87 was significantly higher than that of SGC7901 ( p < 0.05) (f).

Article Snippet: The human gastric cancer cell lines NCI N87 (HER2-positive cell lines) and SGC 7901 (HER2-negative cell lines) were purchased from ATCC.

Techniques: Immunohistochemistry, Western Blot, Expressing, Membrane, Staining

Journal: RSC Advances

Article Title: Targeting HER2-positive gastric cancer with a novel 18 F-labeled Z HER2:342 probe

doi: 10.1039/c8ra10271f

Figure Lengend Snippet: MicroPET imaging and ROI analysis. The images of NCI N87 (0.5 h, 1 h, 2 h, and 4 h p.i.) (a) and SGC7901 (1 h p.i.) models (c) acquired at different time points after administration. Blocking images of the NCI N87 models were also obtained at 1 h p.i. (b). The ROI analysis results are shown in (d) and (e). The uptake data were described as % ID g −1 ( n = 3, mean ± SD).

Article Snippet: The human gastric cancer cell lines NCI N87 (HER2-positive cell lines) and SGC 7901 (HER2-negative cell lines) were purchased from ATCC.

Techniques: Imaging, Blocking Assay

Journal: RSC Advances

Article Title: Targeting HER2-positive gastric cancer with a novel 18 F-labeled Z HER2:342 probe

doi: 10.1039/c8ra10271f

Figure Lengend Snippet: Biodistribution results for 18 FAl-NOTA-MAL-Cys-M 0 -Z HER2:342 in NCI N87 xenograft models ( n = 3 per group)

Article Snippet: The human gastric cancer cell lines NCI N87 (HER2-positive cell lines) and SGC 7901 (HER2-negative cell lines) were purchased from ATCC.

Techniques:

Journal: RSC Advances

Article Title: Targeting HER2-positive gastric cancer with a novel 18 F-labeled Z HER2:342 probe

doi: 10.1039/c8ra10271f

Figure Lengend Snippet: In vivo biodistribution. Biodistribution of the probe in NCI N87 models at different time points after injection (a). Tumor-to-normal tissue ratios of main organs (b). Data are presented as an average ± SD from three animals per group ( n = 3, mean ± SD).

Article Snippet: The human gastric cancer cell lines NCI N87 (HER2-positive cell lines) and SGC 7901 (HER2-negative cell lines) were purchased from ATCC.

Techniques: In Vivo, Injection